Seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds: analysis of its incidence and risk factors

Jpn J Radiol. 2012 Oct;30(8):635-41. doi: 10.1007/s11604-012-0102-7. Epub 2012 Jul 14.

Abstract

Purpose: The purpose of this study was to evaluate the incidence and predictors of seed migration after transperineal interstitial prostate brachytherapy.

Materials and methods: From March 2007 to March 2011, 121 patients with stage T1-T2 prostate cancer underwent transperineal interstitial prostate brachytherapy. Pre-planning was performed 3 weeks prior to implantation, and the implants were inserted using the standard parallel needle insertion technique. All patients underwent a series of radiographs [chest radiography, kidney-ureter-bladder (KUB) radiography, and a CT scan] to assess whether seed migration had occurred on postoperative days 1 and 30, and 12 months.

Results: Seed migration occurred in 31 (25.6 %) of 121 patients. A total of 51 of 7,883 (0.65 %) implanted seeds migrated. Migration was detected on postoperative day 1 in 16 patients, day 30 in 13 patients and at 12 months in 4 patients (migration occurred at different times in 2 patients). The migrated seeds were found in the lungs, pelvis, heart, mediastinum, kidney, inguinal canal, liver and sacrum. The number of needles was a statistically significant factor in seed migration.

Conclusions: The seeds migrated to many organs. No decrease in the dose administered to the prostate or adverse effects associated with seed migration were noted.

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use
  • Brachytherapy* / adverse effects
  • Brachytherapy* / methods
  • Follow-Up Studies
  • Foreign-Body Migration / diagnostic imaging*
  • Foreign-Body Migration / epidemiology
  • Foreign-Body Migration / etiology
  • Humans
  • Incidence
  • Iodine Radioisotopes / administration & dosage*
  • Iodine Radioisotopes / adverse effects
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Perineum
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Radiography
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Iodine Radioisotopes